Bicycle Therapeutics
$29.739876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$29.73
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$2.70 (+9.99%) As of 8:50 PM UTC today
Why Robinhood?
You can buy or sell BCYC and other stocks, options, and ETFs commission-free!
About BCYC
Bicycle Therapeutics plc American Depositary Shares, also called Bicycle Therapeutics, is a holding company, which engages in the development of biopharmaceuticals. It focuses on developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom. The listed name for BCYC is Bicycle Therapeutics plc American Depositary Shares.
CEO
Kevin Lee
Employees
72
Headquarters
Cambridge, Cambridgeshire
Founded
2009
Market Cap
461.24M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
238.13K
High Today
$31.02
Low Today
$26.97
Open Price
$28.05
Volume
624.10K
52 Week High
$31.02
52 Week Low
$10.26
Collections
Analyst Ratings
100%
of 8 ratings
Buy
100%
Hold
0%
Sell
0%
BCYC Earnings
-$1.40
-$0.93
-$0.47
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 9, Pre-Market